BioSig Technologies Inc Stock Price, News & Analysis

BioSig Technologies (NASDAQ: BSGM) has launched the PURE EP™ Software Version 4, enhancing their signal processing technology for irregular heartbeats. This upgrade improves user experience and introduces features like faster real-time signal analysis and a more efficient case setup process. The software rollout will benefit both new and existing customers. Over 660 patient cases have already utilized the PURE EP™ System across eight clinical sites. The company aims to drive innovation and boost commercial sales as part of their growth strategy.

BioSig Technologies, Inc. (BSGM) has completed enrollment for its PURE EP 2.0 clinical trial, involving 51 patients across multiple prestigious hospitals, including Mayo Clinic and Massachusetts General Hospital. The trial aims to validate the effectiveness of the PURE EP System against traditional cardiac signal sources. BioSig anticipates announcing results in Q3 2021, with further insights expected at the Heart Rhythm 2021 convention in late July. The PURE EP System, already FDA cleared, is designed to enhance signal fidelity, potentially leading to improved procedure efficacy and reduced healthcare costs.

BioSig Technologies (NASDAQ: BSGM) has joined the Alliance for Artificial Intelligence in Healthcare (AAIH), enhancing its commitment to AI solutions in healthcare following recent patent awards. The AAIH includes major players like Amazon and Bayer, focusing on improving care quality and reducing costs. BioSig has also launched an AI collaboration with the Mayo Foundation to enhance its PURE EP™ System, which aids in treating arrhythmias. The AI healthcare market is projected to grow from $4.9 billion in 2020 to $45.2 billion by 2026, indicating significant opportunities for BioSig.

BioSig Technologies (BSGM) announced the PURE EP™ System's significance in cardiac ablations, highlighted in EP Lab Digest's April issue. The system is regarded as vital for capturing intracardiac signals, influencing treatment decisions during procedures. Dr. Deepak Gaba noted its superior signal quality, with over 680 cases conducted. The technology supports various arrhythmias and is gaining acceptance among physicians, as it addresses unmet clinical needs. The company plans to leverage accumulated data to develop AI and machine learning applications for electrophysiology.

BioSig Technologies, Inc. (NASDAQ: BSGM) announced the adoption of its PURE EP™ systems by a leading healthcare institution across multiple states. This expansion follows the resumption of elective procedures, contributing to anticipated sales growth. With over 680 cases performed using the PURE EP™ System, which addresses various arrhythmias, the company accumulates vital data for its AI platform. CEO Kenneth L. Londoner expressed optimism about future sales and the acceptance of their technology among leading electrophysiologists.

BioSig Technologies (Nasdaq: BSGM) will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 3 PM ET. CEO Ken Londoner will share insights about the company’s PURE EP™ System, which enhances signal fidelity in electrophysiology. This system has been utilized by over 40 physicians in more than 600 patient cases across eight clinical sites. Interested parties can schedule one-on-one meetings and view the live webcast via the provided links.

BioSig Technologies, Inc. (NASDAQ: BSGM) has announced that the U.S. Patent Office allowed a utility patent for its PURE EP™ technology, focusing on noise-filtering methods for cardiac signals. This innovation is crucial for accurately diagnosing and treating cardiac arrhythmias, particularly atrial fibrillation, which affects over 6 million Americans. The company now holds 34 patents globally for its PURE EP™ technology, enhancing its competitive position in the medical technology market. This new patent complements its patent portfolio and will assist medical teams in improving patient outcomes.

BioSig Technologies (NASDAQ: BSGM) announced significant advances in its operations, including the first commercial sale of the PURE EP™ System to St. David’s HealthCare and over 643 patient cases conducted. The company is expanding its clinical reach with additional sites due to begin evaluations soon. Furthermore, BioSig is developing novel nerve sensing technology and artificial intelligence solutions in collaboration with Mayo Clinic. With a robust cash position of $28.3 million, BioSig is poised for growth and innovation in 2021.

BioSig Technologies, Inc. (Nasdaq: BSGM) will present at the Benzinga Biotech Small Cap Conference on March 24-25, 2021. Kenneth L. Londoner, Chairman and CEO, is scheduled to speak on March 25th at 12:20 PM ET. He will discuss recent milestones related to the PURE EP™ System, an advanced platform aimed at improving cardiac ablations. Over 40 physicians have utilized the system in more than 600 patient cases across eight clinical sites. One-on-one meetings with management can be scheduled through links provided in the release.